COMPARISON OF DOSE ESCALATION AND COSTS OF DOSE ESCALATION BETWEEN PATIENTS WITH RHEUMATOID ARTHRITIS INITIATING BIOLOGIC TREATMENT WITH ETANERCEPT, ADALIMUMAB, OR INFLIXIMAB
May 1, 2016, 00:00
10.1016/j.jval.2016.03.1129
https://www.valueinhealthjournal.com/article/S1098-3015(16)01197-9/fulltext
Title :
COMPARISON OF DOSE ESCALATION AND COSTS OF DOSE ESCALATION BETWEEN PATIENTS WITH RHEUMATOID ARTHRITIS INITIATING BIOLOGIC TREATMENT WITH ETANERCEPT, ADALIMUMAB, OR INFLIXIMAB
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(16)01197-9&doi=10.1016/j.jval.2016.03.1129
First page :
A229
Section Title :
Muscular-Skeletal Disorders - Cost Studies
Open access? :
No
Section Order :
797